BillionToOne (BLLN) Stock Overview

A precision diagnostics company, quantifies biology to create molecular diagnostics. More details

BLLN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue grew by 86.7% over the past year

Risk Analysis

Shares are highly illiquid

Less than 3 years of financial data is available

BLLN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

BillionToOne, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BillionToOne
Historical stock prices
Current Share Price	US$100.03
52 Week High	US$123.84
52 Week Low	US$95.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-8.18%

Recent updates

Shareholder Returns

	BLLN	US Healthcare	US Market
7D	n/a	-0.6%	-2.0%
1Y	n/a	-23.6%	12.1%

Return vs Industry: Insufficient data to determine how BLLN performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how BLLN performed against the US Market.

Price Volatility

Is BLLN's price volatile compared to industry and market?
BLLN volatility
BLLN Average Weekly Movement	n/a
Healthcare Industry Average Movement	6.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.0%

Stable Share Price: BLLN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BLLN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	620	Oguzhan Atay	www.billiontoone.com

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment.

BillionToOne, Inc. Fundamentals Summary

How do BillionToOne's earnings and revenue compare to its market cap?
BLLN fundamental statistics
Market cap	US$4.47b
Earnings (TTM)	-US$30.61m
Revenue (TTM)	US$209.03m

21.4x

P/S Ratio

-146.1x

P/E Ratio

Is BLLN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLLN income statement (TTM)
Revenue	US$209.03m
Cost of Revenue	US$81.66m
Gross Profit	US$127.37m
Other Expenses	US$157.99m
Earnings	-US$30.61m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.68
Gross Margin	60.93%
Net Profit Margin	-14.65%
Debt/Equity Ratio	30.7%

How did BLLN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/09 02:43
End of Day Share Price	2025/11/07 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BillionToOne, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

BillionToOne, Inc.NasdaqGS:BLLN Stock Report